The Latest Breaking News from Novo Nordisk

Pharma companies are slashing insulin production in favour of more lucrative weight-loss drugs.

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

Nvidia and Novo Nordisk's joint venture, Gefion, represents a groundbreaking endeavor in medical research, leveraging AI technology.

Novo Nordisk Foundation expands global grant allocation to drive research and innovation beyond Denmark, fostering collaborations and excellence worldwide.

FDA approves Novo Nordisk's Wegovy for reducing heart risks in weight management. Novo Nordisk's innovative solution targets weight management and heart risks.

The popular weight-loss drug can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, the FDA said.